Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Outset Medical, Inc. Common Stock

OM

Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.

Last trade $3.22
Day change -$0.17 (-5.01%)
Day range $3.14 – $3.82
Volume 91,669
Market cap $64M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$63.98M
Price / earnings
—
Price / book
0.77×
Price / sales
0.52×
EV / sales
1.07×
EV / EBITDA
-2.19×

Profitability

Earnings per share
-$3.77
Return on assets
-30.88%
Return on equity
-85.39%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.2×
Current ratio
4.86×
Quick ratio
3.85×
Cash ratio
0.76×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$42.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for OM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$33.6M$31.64M$27.86M$28.87M$29.43M$31.42M$29.75M$29.47M
Cost of revenue$19.93M$18.35M$15.77M$16.64M$17.84M$19.55M$18.69M$18.72M
Gross profit$13.67M$13.28M$12.1M$12.23M$11.59M$11.87M$11.07M$10.75M
Selling, general and administrative$20.04M$23.51M$23.4M$24.81M$22.03M$23.44M$21.95M$24.72M
Research and development$5.9M$5.45M$5.62M$5.06M$5.38M$5.29M$5.52M$7.89M
Total operating expenses$25.94M$28.96M$29.01M$29.86M$27.4M$28.73M$27.47M$32.61M
Operating income-$12.27M-$15.68M-$16.92M-$17.63M-$15.81M-$16.87M-$16.4M-$21.86M
Interest expense-$3.51M-$3.44M-$3.37M-$3.44M-$3.48M-$3.48M-$3.56M-$5.83M
Income before taxes-$14.53M-$17.76M-$18.76M-$19.4M-$17.43M-$18.44M-$25.67M-$25.64M
Income taxes$153K$220K$217K$95K$404K$104K$115K-$4K
Net income-$14.69M-$17.98M-$18.98M-$19.49M-$17.84M-$18.54M-$25.78M-$25.64M
Net income attributable to common shareholders-$14.69M-$17.98M-$18.98M-$19.49M-$17.84M-$18.54M-$25.78M-$25.64M
EBITDA-$11.6M-$15.05M-$16.12M-$16.75M-$14.8M-$15.71M-$15.11M-$20.45M
Basic earnings per share-$0.78-$0.97-$1.03-$1.07-$1.00-$1.04-$3.66-$7.29
Diluted earnings per share-$0.78-$0.97-$1.03-$1.07-$1.00-$1.04-$3.66-$7.29

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

All You Need to Know About Outset Medical (OM) Rating Upgrade to Buy

Outset Medical, Inc. (OM) received an upgrade to Zacks Rank #2 (Buy) due to rising earnings estimate revisions over the past three months, positioning it in the top 20% of Zacks-covered stocks. The upgrade reflects improving business fundamentals and suggests potential near-term stock price appreciation.

Zacks Investment Research

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market.

Zacks Investment Research

Reasons to Retain Hims & Hers Stock in Your Portfolio for Now

Hims & Hers (HIMS) is accelerating growth through weight loss offerings, international expansion, and AI-enabled care, with U.S. revenues up 16% and international revenues surging 17-fold. However, the company faces headwinds from gross margin compression due to lower-margin branded products, negative cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock has gained 49.5% in six months but carries a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?

Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 20, 20251-for-15reverse split